GLP1R and steatosis: The reduction in steatosis in the GLP-1R agonist-treated group was accompanied by suppressed expression of hepatic genes for de novo lipogenesis (Acc1, Srebp1c and Fasn), for reactive oxygen stress (Nrf2, Nox2) and inflammation (Mpo, Il-6, Il-12) (Fig. 1C–E).